Life Sciences
-
One of the Largest Life Sciences Practices in the U.S.
Wilson Sonsini's Life Sciences practice is one of the largest in the U.S., with more than 275 professionals, including attorneys, patent agents, and scientific advisors.
-
Our Attorneys Act as Strategic General Counsel, Advising on a Comprehensive Scope of Business Operations and Issues
Wilson Sonsini's attorneys often act as strategic general counsel, drawing from their broader scope of experience and advising on matters beyond patents and IP.
-
A Nationally Recognized and Ranked Life Sciences Practice
Recognized as a “Leading Firm” for Life Sciences—in Nationwide, California, and Massachusetts categories—in the 2025 edition of Chambers USA: America’s Leading Lawyers for Business. The firm was also named a finalist in two “Firm of the Year” categories: Corporate Firm of the Year and Hatch-Waxman Litigation Firm of the Year (Generic) of the LMG Life Sciences 2024 Americas Awards.
A Legacy of Life Sciences Leadership
The firm has a 60-plus year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients.
Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry. A central pillar of our Life Sciences practice is our longstanding representation of medical device and biopharmaceutical companies, entrepreneurs, and investors, which dates back to these industries’ inception.
Wilson Sonsini’s Life Sciences practice is anchored by a diverse team of attorneys, patent agents, and scientific advisors, more than 100 of whom hold Ph.D.s and have significant industry experience. The team also includes former in-house legal counsel for major life sciences companies, an internationally recognized leader in the field of technology transfer, and former senior officials at U.S. federal agencies, such as the U.S. Patent and Trademark Office (USPTO) and the Patent Trial and Appeal Board (PTAB).
Key Points About Our Practice
On behalf of our life sciences clients, Wilson Sonsini:
- Acted as trusted advisors to 1,800+ private and 170+ publicly traded life sciences companies
- Completed hundreds of public offerings and M&A transactions with a combined value of more than $122.5 billion between 2020-2025
- Raised 1,500+ venture rounds totaling over $38.1 billion
- Counseled hundreds of life sciences companies on structuring strategic commercial collaborations
Our Nexus to Life Sciences Innovation
For decades, Wilson Sonsini has advised and worked closely with life sciences industry icons who were responsible novel and ground-breaking inventions, such as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. As the industry has expanded, so has the scope of Wilson Sonsini's work with life sciences innovators, institutions, and investors. In fact, our team has represented clients in the following life sciences fields:
|
|
Our Inter-Disciplinary Team and Comprehensive Scope of Practice
Our work with life sciences companies to help them develop and implement their business strategies encompasses:
- Patents and Innovation Strategy – We help founders of growing life sciences companies formulate actionable business strategies focused on building and protecting robust and valuable patent portfolios, while also helping established companies protect groundbreaking discoveries.
- Life Sciences Commercial and Technology Transactions – We represent clients in complex commercial and other technology and licensing transactions, including bet-the-company complex commercial collaborations and their foundational intellectual property licenses.
- Corporate – We address the broad corporate needs of our life sciences clients, including helping them raise private and public capital and advising them on complicated M&A structures. The firm has represented companies in more venture financing transactions than any other U.S. law firm.
- Healthcare and FDA Regulatory – We advise life sciences clients on regulatory strategies for their products and services, including representing them in regulatory matters before the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and other federal and state consumer protection agencies.
- Life Sciences Business Advisory Practice – We offer business advisory capabilities that complement our firm’s legal representation. Our Business Advisory practice helps emerging and established life sciences companies execute business strategies, including crafting and enhancing their business plans; raising capital; recruiting and retaining their teams; and structuring, negotiating, and managing strategic transactions.
- Intellectual Property Litigation – We represent life sciences companies in a broad range of IP disputes and complex litigation, including patent, trade secret, trademark, and copyright matters.
Overview
A Legacy of Life Sciences Leadership
The firm has a 60-plus year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients.
Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry. A central pillar of our Life Sciences practice is our longstanding representation of medical device and biopharmaceutical companies, entrepreneurs, and investors, which dates back to these industries’ inception.
Wilson Sonsini’s Life Sciences practice is anchored by a diverse team of attorneys, patent agents, and scientific advisors, more than 100 of whom hold Ph.D.s and have significant industry experience. The team also includes former in-house legal counsel for major life sciences companies, an internationally recognized leader in the field of technology transfer, and former senior officials at U.S. federal agencies, such as the U.S. Patent and Trademark Office (USPTO) and the Patent Trial and Appeal Board (PTAB).
Key Points About Our Practice
On behalf of our life sciences clients, Wilson Sonsini:
- Acted as trusted advisors to 1,800+ private and 170+ publicly traded life sciences companies
- Completed hundreds of public offerings and M&A transactions with a combined value of more than $122.5 billion between 2020-2025
- Raised 1,500+ venture rounds totaling over $38.1 billion
- Counseled hundreds of life sciences companies on structuring strategic commercial collaborations
Our Nexus to Life Sciences Innovation
For decades, Wilson Sonsini has advised and worked closely with life sciences industry icons who were responsible novel and ground-breaking inventions, such as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. As the industry has expanded, so has the scope of Wilson Sonsini's work with life sciences innovators, institutions, and investors. In fact, our team has represented clients in the following life sciences fields:
|
|
Our Inter-Disciplinary Team and Comprehensive Scope of Practice
Our work with life sciences companies to help them develop and implement their business strategies encompasses:
- Patents and Innovation Strategy – We help founders of growing life sciences companies formulate actionable business strategies focused on building and protecting robust and valuable patent portfolios, while also helping established companies protect groundbreaking discoveries.
- Life Sciences Commercial and Technology Transactions – We represent clients in complex commercial and other technology and licensing transactions, including bet-the-company complex commercial collaborations and their foundational intellectual property licenses.
- Corporate – We address the broad corporate needs of our life sciences clients, including helping them raise private and public capital and advising them on complicated M&A structures. The firm has represented companies in more venture financing transactions than any other U.S. law firm.
- Healthcare and FDA Regulatory – We advise life sciences clients on regulatory strategies for their products and services, including representing them in regulatory matters before the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and other federal and state consumer protection agencies.
- Life Sciences Business Advisory Practice – We offer business advisory capabilities that complement our firm’s legal representation. Our Business Advisory practice helps emerging and established life sciences companies execute business strategies, including crafting and enhancing their business plans; raising capital; recruiting and retaining their teams; and structuring, negotiating, and managing strategic transactions.
- Intellectual Property Litigation – We represent life sciences companies in a broad range of IP disputes and complex litigation, including patent, trade secret, trademark, and copyright matters.
Client Highlights
Wilson Sonsini Advises Oak Hill Bio on IP Matters in Proposed Business Combination with RACC
On July 27, 2026, OHB Pediatrics Ltd. (dba Oak Hill Bio), a clinical-stage rare disease therapeutics company, and Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announced that they had entered into a definitive business combination agreement. In connection with consummation of the transaction, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol OAKH. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on IP matters related to the transaction.
Alerts
CMS Proposes Payment Frameworks for “Software as a Medical Service”
On July 2, 2026, the Centers for Medicare and Medicaid Services (CMS) released the calendar year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule and on July 14, 2026, subsequently released the CY 2027 Physician Fee Schedule (PFS) proposed rule.1 These proposed rules establish a newly named Medicare payment category, Software as a Medical Service (SaMS), for software that supports clinical decision-making through algorithmic analysis.2 This is CMS’ first effort to pay for software-based clinical services in a structural way as their own category rather than as a cost buried inside reimbursement for another procedure. The consequential impact is that CMS would create a new reimbursement vehicle for software and AI-enabled products to be reimbursed as standalone services in the future. The proposal is worth close attention from stakeholders because Medicare reimbursement often determines the success of software or AI products intended for clinical purposes. Comments are due August 31, 2026, on the OPPS rule and September 14, 2026, on the PFS rule.
Client Highlights
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Client Highlights
Wilson Sonsini Advises NIPRO on Expanded Partnership with Linear Health Sciences
On July 13, 2026, Linear Health Sciences announced that Japanese medical device manufacturer NIPRO will begin distributing its Orchid Safety Release Valve (SRV) in the Japanese market beginning July 22, 2026. The device is designed to prevent unintentional IV catheter dislodgement by introducing a mechanism that safely disconnects when excessive force is applied. Wilson Sonsini Goodrich & Rosati advised NIPRO on the transaction.
Insights
Client Highlights
Wilson Sonsini Advises Oak Hill Bio on IP Matters in Proposed Business Combination with RACC
On July 27, 2026, OHB Pediatrics Ltd. (dba Oak Hill Bio), a clinical-stage rare disease therapeutics company, and Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announced that they had entered into a definitive business combination agreement. In connection with consummation of the transaction, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol OAKH. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on IP matters related to the transaction.
Alerts
CMS Proposes Payment Frameworks for “Software as a Medical Service”
On July 2, 2026, the Centers for Medicare and Medicaid Services (CMS) released the calendar year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule and on July 14, 2026, subsequently released the CY 2027 Physician Fee Schedule (PFS) proposed rule.1 These proposed rules establish a newly named Medicare payment category, Software as a Medical Service (SaMS), for software that supports clinical decision-making through algorithmic analysis.2 This is CMS’ first effort to pay for software-based clinical services in a structural way as their own category rather than as a cost buried inside reimbursement for another procedure. The consequential impact is that CMS would create a new reimbursement vehicle for software and AI-enabled products to be reimbursed as standalone services in the future. The proposal is worth close attention from stakeholders because Medicare reimbursement often determines the success of software or AI products intended for clinical purposes. Comments are due August 31, 2026, on the OPPS rule and September 14, 2026, on the PFS rule.
Client Highlights
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Client Highlights
Wilson Sonsini Advises NIPRO on Expanded Partnership with Linear Health Sciences
On July 13, 2026, Linear Health Sciences announced that Japanese medical device manufacturer NIPRO will begin distributing its Orchid Safety Release Valve (SRV) in the Japanese market beginning July 22, 2026. The device is designed to prevent unintentional IV catheter dislodgement by introducing a mechanism that safely disconnects when excessive force is applied. Wilson Sonsini Goodrich & Rosati advised NIPRO on the transaction.
Affiliated Programs
Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
This full-day workshop will be taught by accomplished business development (BD) professionals with deep experience in both large pharmas and small biotechs, providing perspectives from both sides of the table for biopartnering. If you have ever wondered what BD is, how to work efficiently and effectively with your BD team to advance your company’s strategy and programs, or even how to become a BD professional yourself, this is a good workshop for you (and your colleagues in R&D, regulatory, legal, finance, and even executive positions) to attend. The workshop will include presentations, case studies, and group exercises, and conclude with a panel discussion.
Affiliated Programs
Intellectual Property (IP) for Antibody and Related Therapeutics: Strategies, Best Practices and Case Studies
Antibody and related biologic therapeutics present unique intellectual property (IP) challenges throughout discovery, development, and commercialization. This online workshop will bring together IP attorneys and industry experts from Haynes Boone, Wilson Sonsini, Morgan Lewis, Morrison Foerster, and Amgen to discuss practical strategies, emerging legal issues, and real-world case studies. Attendees will gain insights into protecting innovation, managing IP risks, and navigating an evolving legal landscape shaped by advances in biologics and AI.
Affiliated Programs
East Coast NextGen VC Forum 2026
LaunchBio’s NextGen VC Forum is the premier event for venture capital professionals to deepen their knowledge of the life science and biotech sectors while building meaningful connections across the industry. The forum features expert led sessions that offer practical insights into evaluating, supporting, and scaling science-backed startups. Networking is built into the program to help participants expand their reach and grow their networks. Co-created with Wilson Sonsini, the half-day forum includes a networking lunch, three interactive one-hour sessions, and a closing happy hour.
Affiliated Programs
West Coast NextGen VC Forum
LaunchBio’s NextGen VC Forum is the premier event for venture capital professionals to deepen their knowledge of the life science and biotech sectors while building meaningful connections across the industry. The forum features expert led sessions that offer practical insights into evaluating, supporting, and scaling science-backed startups. Networking is built into the program to help participants expand their reach and grow their networks. Co-created with Wilson Sonsini, the half-day forum includes a networking lunch, three interactive one-hour sessions, and a closing happy hour.
Events
Affiliated Programs
Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
This full-day workshop will be taught by accomplished business development (BD) professionals with deep experience in both large pharmas and small biotechs, providing perspectives from both sides of the table for biopartnering. If you have ever wondered what BD is, how to work efficiently and effectively with your BD team to advance your company’s strategy and programs, or even how to become a BD professional yourself, this is a good workshop for you (and your colleagues in R&D, regulatory, legal, finance, and even executive positions) to attend. The workshop will include presentations, case studies, and group exercises, and conclude with a panel discussion.
Affiliated Programs
Intellectual Property (IP) for Antibody and Related Therapeutics: Strategies, Best Practices and Case Studies
Antibody and related biologic therapeutics present unique intellectual property (IP) challenges throughout discovery, development, and commercialization. This online workshop will bring together IP attorneys and industry experts from Haynes Boone, Wilson Sonsini, Morgan Lewis, Morrison Foerster, and Amgen to discuss practical strategies, emerging legal issues, and real-world case studies. Attendees will gain insights into protecting innovation, managing IP risks, and navigating an evolving legal landscape shaped by advances in biologics and AI.
Affiliated Programs
East Coast NextGen VC Forum 2026
LaunchBio’s NextGen VC Forum is the premier event for venture capital professionals to deepen their knowledge of the life science and biotech sectors while building meaningful connections across the industry. The forum features expert led sessions that offer practical insights into evaluating, supporting, and scaling science-backed startups. Networking is built into the program to help participants expand their reach and grow their networks. Co-created with Wilson Sonsini, the half-day forum includes a networking lunch, three interactive one-hour sessions, and a closing happy hour.
Affiliated Programs
West Coast NextGen VC Forum
LaunchBio’s NextGen VC Forum is the premier event for venture capital professionals to deepen their knowledge of the life science and biotech sectors while building meaningful connections across the industry. The forum features expert led sessions that offer practical insights into evaluating, supporting, and scaling science-backed startups. Networking is built into the program to help participants expand their reach and grow their networks. Co-created with Wilson Sonsini, the half-day forum includes a networking lunch, three interactive one-hour sessions, and a closing happy hour.
Ali R. Alemozafar
Partner
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
Matthew A. Argenti
Partner
Matt is an experienced patent litigatior with an focus on post-grant review proceedings before the PTAB.
Hin Au
Partner
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Mark W. Bellomy
Partner
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
Miranda Biven
Partner
Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.
Lance E. Brady
Partner
Lance Brady is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office, where his practice focuses on representing public and private life sciences and technology companies through all stages of their growth. Lance advises his clients on a broad variety of transactions and corporate matters, including initial formation and organization, equity and debt financings, mergers and acquisitions, public offerings, spin-outs, corporate governance, SEC compliance and public company reporting requirements. He also has extensive experience representing venture capital and other institutional investors in financing transactions.
Jason Breen
Partner
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.
Nellie J. Brutocao
Partner
Nellie Brutocao is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, representing public and private companies in intellectual property and commercial transactions, including strategic alliances, research and development collaborations, technology licenses and acquisitions, supply, distribution and manufacturing agreements, sponsored research agreements, clinical trials arrangements, material transfer agreements, and co-promotion arrangements. She has also represented life sciences companies in complex commercial and patent disputes, including Hatch-Waxman litigation.
Kassandra K. Castillo
Partner
Kassandra K. Castillo practices corporate and securities law in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she serves as outside general counsel and advises life sciences and technology companies at all stages of development. She works closely with entrepreneurs to counsel them through initial company formation issues, day-to-day corporate governance matters, venture capital financing transactions, and liquidity events. She also counsels venture capital funds on structuring and executing investment transactions and managing their existing portfolio companies.
People
Ali R. Alemozafar
Partner
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
Matthew A. Argenti
Partner
Matt is an experienced patent litigatior with an focus on post-grant review proceedings before the PTAB.
Hin Au
Partner
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
Mark B. Baudler
Partner
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
Mark W. Bellomy
Partner
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
Miranda Biven
Partner
Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.
Lance E. Brady
Partner
Lance Brady is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office, where his practice focuses on representing public and private life sciences and technology companies through all stages of their growth. Lance advises his clients on a broad variety of transactions and corporate matters, including initial formation and organization, equity and debt financings, mergers and acquisitions, public offerings, spin-outs, corporate governance, SEC compliance and public company reporting requirements. He also has extensive experience representing venture capital and other institutional investors in financing transactions.
Jason Breen
Partner
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.
Nellie J. Brutocao
Partner
Nellie Brutocao is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, representing public and private companies in intellectual property and commercial transactions, including strategic alliances, research and development collaborations, technology licenses and acquisitions, supply, distribution and manufacturing agreements, sponsored research agreements, clinical trials arrangements, material transfer agreements, and co-promotion arrangements. She has also represented life sciences companies in complex commercial and patent disputes, including Hatch-Waxman litigation.
Kassandra K. Castillo
Partner
Kassandra K. Castillo practices corporate and securities law in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she serves as outside general counsel and advises life sciences and technology companies at all stages of development. She works closely with entrepreneurs to counsel them through initial company formation issues, day-to-day corporate governance matters, venture capital financing transactions, and liquidity events. She also counsels venture capital funds on structuring and executing investment transactions and managing their existing portfolio companies.
Related Industries
Recent Insights
Client Highlights
Wilson Sonsini Advises Oak Hill Bio on IP Matters in Proposed Business Combination with RACC
On July 27, 2026, OHB Pediatrics Ltd. (dba Oak Hill Bio), a clinical-stage rare disease therapeutics company, and Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announced that they had entered into a definitive business combination agreement. In connection with consummation of the transaction, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol OAKH. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on IP matters related to the transaction.
Learn More
Recent Events
Affiliated Programs
Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
This full-day workshop will be taught by accomplished business development (BD) professionals with deep experience in both large pharmas and small biotechs, providing perspectives from both sides of the table for biopartnering. If you have ever wondered what BD is, how to work efficiently and effectively with your BD team to advance your company’s strategy and programs, or even how to become a BD professional yourself, this is a good workshop for you (and your colleagues in R&D, regulatory, legal, finance, and even executive positions) to attend. The workshop will include presentations, case studies, and group exercises, and conclude with a panel discussion.
Learn More
Affiliated Programs
Intellectual Property (IP) for Antibody and Related Therapeutics: Strategies, Best Practices and Case Studies
Antibody and related biologic therapeutics present unique intellectual property (IP) challenges throughout discovery, development, and commercialization. This online workshop will bring together IP attorneys and industry experts from Haynes Boone, Wilson Sonsini, Morgan Lewis, Morrison Foerster, and Amgen to discuss practical strategies, emerging legal issues, and real-world case studies. Attendees will gain insights into protecting innovation, managing IP risks, and navigating an evolving legal landscape shaped by advances in biologics and AI.
Learn More
Newsletters
2025 Mid-Year Technology and Life Sciences PIPE and RDO Report
Dive into our mid-year review of 68 PIPEs and RDOs by U.S. technology and life sciences firms between January 1 and June 30, 2025. Key findings include a decline in life sciences activity and robust strength in the technology sector.
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.